Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).
The companies previously announced the submission of a regulatory application in the US on December 18th.
The firms also plan to make submissions for regulatory approval for UMEC monotherapy later this year.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Glaxo's share price rose 0.44% to 1,379.50p by 13:22.
NR
-
Nvidia's earnings live: stock gains as investors brace for key resultsNvidia's stock opened strongly ahead of its earnings, as analysts question whether Blackwell sales can make up for lost China revenue
-
8 of the best lakeside properties for saleThe best lakeside properties – from a house on the southeastern shore of Loch Lomond, to a 15th-century hall overlooking a lake in King’s Lynn, Norfolk
